imipenem/relebactam / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
imipenem/relebactam / Merck (MSD)
ChiCTR2300070223: An assessment of the Ceftolozane/Tazobactam and Imipenem/Relebactam activity in the hypervirulent Klebsiella pneumoniae

Not yet recruiting
N/A
1000
 
none
Peking University Third Hospital; Peking University Third Hospital, self-financing
Infectious disease
 
 
NCT05285046: Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM

Enrolling by invitation
N/A
250
RoW
No intervention
D'Or Institute for Research and Education
Bacterial Infections, Antibiotic Resistant Infection
10/22
02/23

Download Options